Research in sleep-disordered breathing (SDB) | ResMed

Research in sleep-disordered breathing

An expanding body of scientific evidence clearly indicates that sleep-disordered breathing (SDB) has a profound negative impact on public health. Through its strong partnership with the global medical community, ResMed is committed to: 

  • Increasing awareness of the dangers of untreated SDB 
  • Supporting ongoing research into the correlation between SDB and other health risks 
  • Finding effective clinical solutions to improve the health and lives of SDB patients 

ALASKA - “A nationwide cLAimS data laKe for sleep Apnea"

A large-scale analysis of the French national healthcare database (SNDS*), which explored the patient profiles and PAP adherence of almost half-a-million sleep apnoea patients during their first three years of PAP therapy.

ALASKA study outcomes:
first publication1

ALASKA showed that it’s important to consider patient phenotyping and personalised care when developing integrated sleep apnoea management strategies.
Our infographic highlights the key findings.


ALASKA study results:
second publication2

Chances of survival increased by 39% and the risk of developing heart failure and hypertension reduced for patients continuing PAP treatment throughout the first year: ALASKA’s second publication followed 176,014 PAP patients in the French healthcare system database over 3 years.
For more, download our infographic.


Obstructive sleep apnoea research

Improved compliance, greater efficiencies, higher quality of care – here is some of the latest research that provides evidence of these results.

There’s a growing body of clinical research that demonstrates the efficacy and compliance of mandibular repositioning devices (MRDs) in treating obstructive sleep apnoea and snoring.

Central sleep apnoea research

Switching patients with persistent or emergent CSA from CPAP to ASV may improve compliance. Learn more about the findings from this big data study.

SERVE-HF has become a key study in its field, contributing significantly to ASV clinical practice. Learn more about the study design, results and implications for clinical practice.

The FACE study will provide long-term data on morbidity and mortality of heart failure (both HFrEF and HFpEF) patients using ASV.

Support for investigator initiated research

ResMed believes in the need to support ethical, independent clinical research, conducted by qualified third-party investigators.


*Système National des Données de Santé | SNDS –

1 Pépin, J.-L.; Bailly, S.; Rinder, P.; Adler, D.; Szeftel, D.; Malhotra, A.; Cistulli, P.A.; Benjafield, A.; Lavergne, F.; Josseran, A.; et al. CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis. J. Clin. Med. 2021, 10, 936. Retrospective analysis on 480 000 adult patients with CPAP therapy initiated from 2015 to end of 2016, identified in the French Health insurance claims database, and followed up until end of 20192 Pépin JL, et al. Relationship between CPAP termination and all-cause mortality: a French nationwide database analysis, CHEST (2022), doi: analysis of 176 014 adult patients identified in the French health insurance claims database, who started PAP therapy between January 2015 and December 2016 and were followed up for 3 years